{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:54:51Z","timestamp":1790117691051,"version":"4.0.1"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["10150511910059"],"award-info":[{"award-number":["10150511910059"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["10150511910059"],"award-info":[{"award-number":["10150511910059"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["10150511910059"],"award-info":[{"award-number":["10150511910059"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Most European countries offer human papillomavirus (HPV) vaccination through organised immunisation programmes, but the choice of vaccine varies. We compared the expected health and economic effects of the currently used bivalent vaccine, targeting HPV-16\/18, and the nonavalent vaccine, targeting seven additional genotypes, for the Netherlands.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We estimated the incremental impact of nonavalent versus bivalent vaccination in a cohort of 100,000 girls and 100,000 boys offered vaccination at age 10, by projecting type-specific infection risk reductions onto expected number of cervical screening outcomes, HPV-related cancers, and treatments for anogenital warts and recurrent respiratory papillomatosis (RRP). In the base-case, we assumed two-dose vaccination with 60% uptake, lifelong partial cross-protection against HPV-31\/33\/45 for the bivalent vaccine and EUR 25 extra cost per dose for the nonavalent vaccine. Cost-effectiveness was assessed from a healthcare provider perspective by comparing the incremental cost-effectiveness ratio (ICER) per life-year gained (LYG) with the Dutch threshold of EUR 20,000\/LYG.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Compared with bivalent vaccination, nonavalent vaccination prevents an additional 1320 high-grade cervical lesions, 70 cancers, 34,000 anogenital warts episodes and 30 RRPs and generates EUR 4.1 million discounted savings from fewer treatments. The ICER is EUR 5489 (95% credible interval: 3765; 7019)\/LYG in the base-case and exceeds the cost-effectiveness threshold only if the cross-protection for the bivalent vaccine extends permanently to non-31\/33\/45 genotypes or if the vaccine efficacy wanes past age 20 for\u00a0both vaccines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Sex-neutral vaccination with the nonavalent vaccine is likely to be cost-effective. Long-term monitoring of type-specific vaccine effectiveness is essential because of the impact of cross-protection and waning efficacy on cost-effectiveness.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12916-025-04170-3","type":"journal-article","created":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T19:02:12Z","timestamp":1749409332000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Projected health and economic effects of nonavalent versus bivalent human papillomavirus vaccination in preadolescence in the Netherlands"],"prefix":"10.1186","volume":"23","author":[{"given":"Birgit","family":"Sollie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Berkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes A.","family":"Bogaards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,9]]},"reference":[{"key":"4170_CR1","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/nrc.2018.13","volume":"18","author":"RBS Roden","year":"2018","unstructured":"Roden RBS, Stern PL. Opportunities and challenges for human papillomavirus vaccination in cancer. Nat Rev Cancer. 2018;18:240\u201354.","journal-title":"Nat Rev Cancer"},{"key":"4170_CR2","unstructured":"European Medicines Agency. EPAR - assessment report Cervarix. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/cervarix-h-c-000721-p46-102-epar-assessment-report_en.pdf. Accessed 17 May 2025."},{"key":"4170_CR3","unstructured":"European Medicines Agency. EPAR - assessment report Gardasil. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/gardasil-h-c-703-p46-091-epar-assessment-report_en.pdf. Accessed 17 May 2025."},{"key":"4170_CR4","unstructured":"European Medicines Agency. EPAR - assessment report Gardasil 9. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/gardasil-9-h-c-3852-p46-014-epar-assessment-report_en.pdf. Accessed 17 May 2025."},{"key":"4170_CR5","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s10198-018-0996-9","volume":"20","author":"V Qendri","year":"2019","unstructured":"Qendri V, Bogaards JA, Berkhof J. Pricing of HPV vaccines in European tender-based settings. Eur J Health Econ. 2019;20:271\u201380.","journal-title":"Eur J Health Econ"},{"key":"4170_CR6","unstructured":"EU Tenders Electronic Daily. Supplement to the official journal of the EU. https:\/\/ted.europa.eu\/en\/. Accessed 17 May 2025."},{"key":"4170_CR7","unstructured":"Berkhof J, Costa S. Update on the pricing of HPV vaccines in European tender-based settings. EU4H PERCH report 101075314. 2024."},{"key":"4170_CR8","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1093\/infdis\/jiz280","volume":"220","author":"JA Bogaards","year":"2019","unstructured":"Bogaards JA, van der Weele P, Woestenberg PJ, van Benthem BHB, King AJ. Bivalent human papillomavirus (HPV) vaccine effectiveness correlates with phylogenetic distance from HPV vaccine types 16 and 18. J Infect Dis. 2019;220:1141\u20136.","journal-title":"J Infect Dis"},{"key":"4170_CR9","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1586\/14760584.2016.1124763","volume":"15","author":"SR Skinner","year":"2016","unstructured":"Skinner SR, Apter D, De Carvalho N, Harper DM, Konno R, Paavonen J, et al. Human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases. Expert Rev Vaccines. 2016;15:367\u201387.","journal-title":"Expert Rev Vaccines"},{"key":"4170_CR10","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/S1473-3099(17)30468-1","volume":"17","author":"K Kavanagh","year":"2017","unstructured":"Kavanagh K, Pollock KG, Cuschieri K, Palmer T, Cameron RL, Watt C, et al. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study. Lancet Infect Dis. 2017;17:1293\u2013302.","journal-title":"Lancet Infect Dis"},{"key":"4170_CR11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/infdis\/jix582","volume":"217","author":"PJ Woestenberg","year":"2018","unstructured":"Woestenberg PJ, King AJ, van Benthem BHB, Donken R, Leussink S, van der Klis FRM, et al. Bivalent vaccine effectiveness against type-specific HPV positivity: evidence for cross-protection against oncogenic types among Dutch STI clinic visitors. J Infect Dis. 2018;217:213\u201322.","journal-title":"J Infect Dis"},{"key":"4170_CR12","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1093\/infdis\/jiy067","volume":"217","author":"R Donken","year":"2018","unstructured":"Donken R, King AJ, Bogaards JA, Woestenberg PJ, Meijer CJLM, de Melker HE. High effectiveness of the bivalent human papillomavirus (HPV) vaccine against incident and persistent HPV infections up to 6 years after vaccination in young Dutch women. J Infect Dis. 2018;217:1579\u201389.","journal-title":"J Infect Dis"},{"key":"4170_CR13","doi-asserted-by":"publisher","first-page":"3511","DOI":"10.1002\/ijc.33169","volume":"147","author":"P Gray","year":"2020","unstructured":"Gray P, Kann H, Pimenoff VN, Adhikari I, Eriksson T, Surcel HM, et al. Long-term follow-up of human papillomavirus type replacement among young pregnant Finnish females before and after a community-randomised HPV vaccination trial with moderate coverage. Int J Cancer. 2020;147:3511\u201322.","journal-title":"Int J Cancer"},{"key":"4170_CR14","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1016\/j.vaccine.2020.11.076","volume":"39","author":"DR Brown","year":"2021","unstructured":"Brown DR, Joura EA, Yen GP, Kothari S, Luxembourg A, Saah A, et al. Systematic literature review of cross-protective effect of HPV vaccines based on data from randomized clinical trials and real-world evidence. Vaccine. 2021;39:2224\u201336.","journal-title":"Vaccine"},{"key":"4170_CR15","doi-asserted-by":"publisher","first-page":"5107","DOI":"10.1073\/pnas.1515528113","volume":"113","author":"DP Durham","year":"2016","unstructured":"Durham DP, Ndeffo-Mbah ML, Skrip LA, Jones FK, Bauch CT, Galvani AP. National- and state-level impact and cost-effectiveness of nonavalent HPV vaccination in the United States. Proc Natl Acad Sci U S A. 2016;113:5107\u201312.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4170_CR16","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/14737167.2016.1208087","volume":"17","author":"N Largeron","year":"2017","unstructured":"Largeron N, Petry KU, Jacob J, Bianic F, Anger D, Uhart M. An estimate of the public health impact and cost-effectiveness of universal vaccination with a 9-valent HPV vaccine in Germany. Expert Rev Pharmacoecon Outcomes Res. 2017;17:85\u201398.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"4170_CR17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12962-017-0073-8","volume":"15","author":"FS Mennini","year":"2017","unstructured":"Mennini FS, Bonanni P, Bianic F, de Waure C, Baio G, Plazzotta G, et al. Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy. Cost Eff Resour Alloc. 2017;15:11.","journal-title":"Cost Eff Resour Alloc"},{"key":"4170_CR18","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1080\/21645515.2018.1560770","volume":"15","author":"J De La Fuente","year":"2019","unstructured":"De La Fuente J, Hernandez Aguado JJ, San Mart\u00edn M, Ramirez Boix P, Cedillo G\u00f3mez S, L\u00f3pez N. Estimating the epidemiological impact and cost-effectiveness profile of a nonavalent HPV vaccine in Spain. Hum Vaccin Immunother. 2019;15:1949\u201361.","journal-title":"Hum Vaccin Immunother"},{"key":"4170_CR19","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/1471-0528.15106","volume":"125","author":"SK Tay","year":"2018","unstructured":"Tay SK, Hsu TY, Pavelyev A, Walia A, Kulkarni AS. Clinical and economic impact of school-based nonavalent human papillomavirus vaccine on women in Singapore: a transmission dynamic mathematical model analysis. BJOG. 2018;125:478\u201386.","journal-title":"BJOG"},{"key":"4170_CR20","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1016\/j.vaccine.2021.03.040","volume":"39","author":"LC Phua","year":"2021","unstructured":"Phua LC, Choi HCW, Wu J, Jit M, Low J, Ng K, et al. Cost-effectiveness analysis of the nonavalent human papillomavirus vaccine for the prevention of cervical cancer in Singapore. Vaccine. 2021;39:2255\u201363.","journal-title":"Vaccine"},{"key":"4170_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2021.106688","volume":"150","author":"A Portnoy","year":"2021","unstructured":"Portnoy A, Pedersen K, Trogstad L, Hansen BT, Feiring B, Laake I, et al. Cost-effectiveness of nonavalent HPV vaccine in Norway considering current empirical data and validation. Prev Med. 2021;150: 106688.","journal-title":"Prev Med"},{"key":"4170_CR22","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1080\/13696998.2023.2250194","volume":"26","author":"I Diakite","year":"2023","unstructured":"Diakite I, Nguyen S, Sabale U, Pavelyev A, Saxena K, Tajik AA, et al. Public health impact and cost-effectiveness of switching from bivalent to nonavalent vaccine for human papillomavirus in Norway: incorporating the full health impact of all HPV-related diseases. J Med Econ. 2023;26:1085\u201398.","journal-title":"J Med Econ"},{"key":"4170_CR23","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1080\/14760584.2024.2322543","volume":"23","author":"C Palmer","year":"2024","unstructured":"Palmer C, Dolk C, Sabale U, Wang W, Saxena K. Cost-effectiveness of nonavalent HPV vaccination in the Netherlands. Expert Rev Vaccines. 2024;23:312\u201323.","journal-title":"Expert Rev Vaccines"},{"key":"4170_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h2016","volume":"350","author":"JA Bogaards","year":"2015","unstructured":"Bogaards JA, Wallinga J, Brakenhoff RH, Meijer CJ, Berkhof J. Direct benefit of vaccinating boys along with girls against oncogenic human papillomavirus: Bayesian evidence synthesis. BMJ. 2015;350: h2016.","journal-title":"BMJ"},{"key":"4170_CR25","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1093\/infdis\/jix272","volume":"216","author":"V Qendri","year":"2017","unstructured":"Qendri V, Bogaards JA, Berkhof J. Health and economic impact of a tender-based, sex-neutral human papillomavirus 16\/18 vaccination program in the Netherlands. J Infect Dis. 2017;216:210\u20139.","journal-title":"J Infect Dis"},{"key":"4170_CR26","doi-asserted-by":"publisher","first-page":"e592","DOI":"10.1016\/S2468-2667(20)30209-7","volume":"5","author":"V Qendri","year":"2020","unstructured":"Qendri V, Bogaards JA, Baussano I, Lazzarato F, V\u00e4nsk\u00e4 S, Berkhof J. The cost-effectiveness profile of sex-neutral HPV immunisation in European tender-based settings: a model-based assessment. Lancet Public Health. 2020;5:e592\u2013603.","journal-title":"Lancet Public Health"},{"key":"4170_CR27","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1002\/ijc.33207","volume":"148","author":"F Inturrisi","year":"2021","unstructured":"Inturrisi F, Lissenberg-Witte BI, Veldhuijzen NJ, Bogaards JA, Ronco G, Meijer CJLM, Berkhof J. Estimating the direct effect of human papillomavirus vaccination on the lifetime risk of screen-detected cervical precancer. Int J Cancer. 2021;148:320\u20138.","journal-title":"Int J Cancer"},{"key":"4170_CR28","unstructured":"Van Wees DA, Visser M, van Aar F, Op de Coul ELM, Staritsky LE, Sarink D, et al. Sexually transmitted infections in the Netherlands in 2021. RIVM. 2022."},{"key":"4170_CR29","first-page":"83","volume":"36","author":"C Wijsen","year":"2012","unstructured":"Wijsen C, de Haas S. Seksuele gezondheid in Nederland 2011 [in Dutch]. Tijdschrift voor Seksuologie. 2012;36:83\u20136.","journal-title":"Tijdschrift voor Seksuologie"},{"key":"4170_CR30","unstructured":"Anonymous. Kerncijfers Leefstijlmonitor seksuele gezondheid 2019 [in Dutch]. Rutgers\/Soa Aids Nederland. 2021."},{"key":"4170_CR31","doi-asserted-by":"crossref","unstructured":"Woestenberg PJ, Guevara Morel AE, Bogaards JA, Hooiveld M, Schurink-van 't Klooster TM, Hoebe C, et al. Partial protective effect of bivalent human papillomavirus 16\/18 vaccination against anogenital warts in a large cohort of Dutch primary care patients. Clin Infect Dis. 2021; 73:291\u20137.","DOI":"10.1093\/cid\/ciaa582"},{"key":"4170_CR32","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1007\/s00405-022-07388-6","volume":"279","author":"L Pogoda","year":"2022","unstructured":"Pogoda L, Ziylan F, Smeeing DPJ, Dikkers FG, Rinkel R. Bevacizumab as treatment option for recurrent respiratory papillomatosis: a systematic review. Eur Arch Otorhinolaryngol. 2022;279:4229\u201340.","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"4170_CR33","doi-asserted-by":"crossref","unstructured":"San Giorgi MR, van den Heuvel ER, Tjon Pian Gi RE, Brunings JW, Chirila M, Friedrich G, et al. Age of onset of recurrent respiratory papillomatosis: a distribution analysis. Clin Otolaryngol. 2016; 41:448\u201353.","DOI":"10.1111\/coa.12565"},{"key":"4170_CR34","unstructured":"CBS. Statistics Netherlands. https:\/\/www.cbs.nl\/en-gb. Accessed 17 May 2025."},{"key":"4170_CR35","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1093\/aje\/kwp466","volume":"171","author":"JA Bogaards","year":"2010","unstructured":"Bogaards JA, Xiridou M, Coupe VM, Meijer CJ, Wallinga J, Berkhof J. Model-based estimation of viral transmissibility and infection-induced resistance from the age-dependent prevalence of infection for 14 high-risk types of human papillomavirus. Am J Epidemiol. 2010;171:817\u201325.","journal-title":"Am J Epidemiol"},{"key":"4170_CR36","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1097\/EDE.0000000000001026","volume":"30","author":"BI Lissenberg-Witte","year":"2019","unstructured":"Lissenberg-Witte BI, Bogaards JA, Quint WGV, Berkhof J. Estimating the human papillomavirus genotype attribution in screen-detected high-grade cervical lesions. Epidemiology. 2019;30:590\u20136.","journal-title":"Epidemiology"},{"key":"4170_CR37","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/ijc.20076","volume":"110","author":"NW Bulkmans","year":"2004","unstructured":"Bulkmans NW, Rozendaal L, Snijders PJ, Voorhorst FJ, Boeke AJ, Zandwijken GR, et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer. 2004;110:94\u2013101.","journal-title":"Int J Cancer"},{"key":"4170_CR38","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1002\/ijc.24891","volume":"126","author":"DC Rijkaart","year":"2010","unstructured":"Rijkaart DC, Berkhof J, van Kemenade FJ, Rozendaal L, Verheijen RH, Bulk S, et al. Comparison of HPV and cytology triage algorithms for women with borderline or mild dyskaryosis in population-based cervical screening (VUSA-screen study). Int J Cancer. 2010;126:2175\u201381.","journal-title":"Int J Cancer"},{"key":"4170_CR39","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.eururo.2015.12.007","volume":"69","author":"L Alemany","year":"2016","unstructured":"Alemany L, Cubilla A, Halec G, Kasamatsu E, Quiros B, Masferrer E, et al. Role of human papillomavirus in penile carcinomas worldwide. Eur Urol. 2016;69:953\u201361.","journal-title":"Eur Urol"},{"key":"4170_CR40","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/ijc.28963","volume":"136","author":"L Alemany","year":"2015","unstructured":"Alemany L, Saunier M, Alvarado-Cabrero I, Quiros B, Salmeron J, Shin HR, et al. Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer. 2015;136:98\u2013107.","journal-title":"Int J Cancer"},{"key":"4170_CR41","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1016\/j.ejca.2014.07.018","volume":"50","author":"L Alemany","year":"2014","unstructured":"Alemany L, Saunier M, Tinoco L, Quiros B, Alvarado-Cabrero I, Alejo M, et al. Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples. Eur J Cancer. 2014;50:2846\u201354.","journal-title":"Eur J Cancer"},{"key":"4170_CR42","doi-asserted-by":"publisher","first-page":"3450","DOI":"10.1016\/j.ejca.2013.06.033","volume":"49","author":"S De Sanjose","year":"2013","unstructured":"De Sanjose S, Alemany L, Ordi J, Tous S, Alejo M, Bigby SM, et al. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer. 2013;49:3450\u201361.","journal-title":"Eur J Cancer"},{"key":"4170_CR43","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","volume":"11","author":"S De Sanjose","year":"2010","unstructured":"De Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11:1048\u201356.","journal-title":"Lancet Oncol"},{"key":"4170_CR44","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/S1470-2045(14)70471-1","volume":"15","author":"C Ndiaye","year":"2014","unstructured":"Ndiaye C, Mena M, Alemany L, Arbyn M, Castellsague X, Laporte L, et al. HPV DNA, E6\/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis. Lancet Oncol. 2014;15:1319\u201331.","journal-title":"Lancet Oncol"},{"key":"4170_CR45","doi-asserted-by":"crossref","unstructured":"Drolet M, B\u00e9nard \u00c9, P\u00e9rez N, Brisson M; HPV Vaccination Impact Study Group. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019; 394:497\u2013509.","DOI":"10.1016\/S0140-6736(19)30298-3"},{"key":"4170_CR46","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1016\/S2468-2667(16)30001-9","volume":"1","author":"M Brisson","year":"2016","unstructured":"Brisson M, B\u00e9nard \u00c9, Drolet M, Bogaards JA, Baussano I, V\u00e4nsk\u00e4 S, et al. Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. Lancet Public Health. 2016;1:e8\u201317.","journal-title":"Lancet Public Health"},{"key":"4170_CR47","doi-asserted-by":"crossref","unstructured":"Veijer C, Bes J, Dolk C, Postma MJ, de Jong LA. Epidemiological trends and economic burden of genital warts in Dutch primary care. medRxiv. 2024; 2024.06.03.24307801.","DOI":"10.1101\/2024.06.03.24307801"},{"key":"4170_CR48","unstructured":"Gielgens T, Kliffen T, Berkhof J, Dikkers FG. Annual and direct costs of recurrent respiratory papillomavirus in the Netherlands. Amsterdam UMC. internal report."},{"key":"4170_CR49","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ejca.2010.09.030","volume":"47","author":"IMHJ de Kok","year":"2011","unstructured":"de Kok IMHJ, van Rosmalen J, van Ballegooijen M. Would the effect of HPV vaccination on non-cervical HPV-positive cancers make the difference for its cost-effectiveness? Eur J Cancer. 2011;47:428\u201335.","journal-title":"Eur J Cancer"},{"key":"4170_CR50","unstructured":"Anonymous. Verbetersignalement baarmoederhalsafwijking CIN [in Dutch]. Zinnige Zorg. 2019."},{"key":"4170_CR51","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S1470-2045(18)30763-0","volume":"20","author":"NJ Polman","year":"2019","unstructured":"Polman NJ, Ebisch RMF, Heideman DAM, Melchers WJG, Bekkers RLM, Molijn AC, et al. Performance of human papillomavirus testing on self-collected versus clinician-collected samples for the detection of cervical intraepithelial neoplasia of grade 2 or worse: a randomised, paired screen-positive, non-inferiority trial. Lancet Oncol. 2019;20:229\u201338.","journal-title":"Lancet Oncol"},{"key":"4170_CR52","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1200\/JCO.21.02433","volume":"40","author":"WW Kremer","year":"2022","unstructured":"Kremer WW, Dick S, Heideman DAM, Steenbergen RDM, Bleeker MCG, Verhoeve HR, et al. Clinical regression of high-grade cervical intraepithelial neoplasia is associated with absence of FAM19A4\/miR124-2 DNA methylation (CONCERVE Study). J Clin Oncol. 2022;40:3037\u201346.","journal-title":"J Clin Oncol"},{"key":"4170_CR53","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/S1470-2045(11)70078-X","volume":"12","author":"M Kocken","year":"2011","unstructured":"Kocken M, Helmerhorst TJ, Berkhof J, Louwers JA, Nobbenhuis MA, Bais AG, et al. Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study. Lancet Oncol. 2011;12:441\u201350.","journal-title":"Lancet Oncol"},{"key":"4170_CR54","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/1471-0528.16400","volume":"128","author":"E Jansen","year":"2021","unstructured":"Jansen E, Naber SK, Aitken CA, de Koning HJ, van Ballegooijen M, de Kok I. Cost-effectiveness of HPV-based cervical screening based on first year results in the Netherlands: a modelling study. BJOG. 2021;128:573\u201382.","journal-title":"BJOG"},{"key":"4170_CR55","unstructured":"Van Ballegooijen M, Rebolj M, Essink-Bot ML, Meerding WJ, Berkers LM, Habbema JDF. De effecten en kosten van het bevolkingsonderzoek naar baarmoederhalskanker in Nederland na de herstructurering [in Dutch]. Erasmus MC, Rotterdam. 2006."},{"key":"4170_CR56","unstructured":"IKNL. Netherlands Cancer Registry. https:\/\/iknl.nl\/en. Accessed 17 May 2025."},{"key":"4170_CR57","unstructured":"Zorginstituut Nederland. Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg (versie 2024) [in Dutch]. Available from: https:\/\/www.zorginstituutnederland.nl\/publicaties\/publicatie\/2024\/01\/16\/richtlijn-voor-het-uitvoeren-van-economische-evaluaties-in-de-gezondheidszorg. Accessed 17 May 2025."},{"key":"4170_CR58","unstructured":"Kennisplatform Preventie. Preventie op waarde schatten [in Dutch]. Available from: https:\/\/www.zonmw.nl\/sites\/zonmw\/files\/2024-01\/Preventie-op-waarde-schatten---Advies-technische-werkgroep-kosten-baten-preventie-dec-23_DEF.pdf. Accessed 17 May 2025."},{"key":"4170_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.pvr.2019.100184","volume":"8","author":"K Canfell","year":"2019","unstructured":"Canfell K, Kim JJ, Kulasingam S, Berkhof J, Barnabas R, Bogaards JA, et al. HPV-FRAME: a consensus statement and quality framework for modelled evaluations of HPV-related cancer control. Papillomavirus Res. 2019;8: 100184.","journal-title":"Papillomavirus Res"},{"key":"4170_CR60","unstructured":"Van Roon AM, Lanooij SJ, De Melker HE (Eds.) The National Immunisation Programme in the Netherlands: surveillance and developments in 2023\u20132024. RIVM report 2024\u20130072. 2024."},{"key":"4170_CR61","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1405044","volume":"372","author":"EA Joura","year":"2015","unstructured":"Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372:711\u201323.","journal-title":"N Engl J Med"},{"key":"4170_CR62","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1093\/infdis\/jiab250","volume":"226","author":"J Hoes","year":"2022","unstructured":"Hoes J, King AJ, Klooster TMSV, Berkhof J, Bogaards JA, de Melker HE. Vaccine effectiveness following routine immunization with bivalent human papillomavirus (HPV) vaccine: protection against incident genital HPV infections from a reduced-dosing schedule. J Infect Dis. 2022;226:634\u201343.","journal-title":"J Infect Dis"},{"key":"4170_CR63","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.vaccine.2022.11.057","volume":"41","author":"J Hoes","year":"2023","unstructured":"Hoes J, King AJ, Berkhof J, de Melker HE. High vaccine effectiveness persists for ten years after HPV16\/18 vaccination among young Dutch women. Vaccine. 2023;41:285\u20139.","journal-title":"Vaccine"},{"key":"4170_CR64","doi-asserted-by":"crossref","unstructured":"Kusters JMA, Schim van der Loeff MF, van Benthem BHB, King AJ, De Melker HE, Heijman T, et al. Effectiveness of bivalent HPV vaccination against genital HPV DNA-positivity of a catch-up campaign at age 13\u201316 years compared to routine vaccination at age 12 years: a biennial repeated cross-sectional study. BMC Med. 2024; 22:469.","DOI":"10.1186\/s12916-024-03686-4"},{"key":"4170_CR65","doi-asserted-by":"crossref","unstructured":"Restrepo J, Herrera T, Samakoses R, Reina JC, Pitisuttithum P, Ulied A, et al. Ten-year follow-up of 9-valent human papillomavirus vaccine: immunogenicity, effectiveness, and safety. Pediatrics. 2023; 152e2022060993.","DOI":"10.1542\/peds.2022-060993"},{"key":"4170_CR66","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1093\/infdis\/jiaa007","volume":"221","author":"J Hoes","year":"2020","unstructured":"Hoes J, Pasmans H, Knol MJ, Donken R, van Marm-Wattimena N, Schepp RM, et al. Persisting antibody response 9 years after bivalent human papillomavirus (HPV) vaccination in a cohort of Dutch women: immune response and the relation to genital HPV infections. J Infect Dis. 2020;221:1884\u201394.","journal-title":"J Infect Dis"},{"key":"4170_CR67","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1093\/infdis\/jiaa617","volume":"223","author":"H Kann","year":"2021","unstructured":"Kann H, Lehtinen M, Eriksson T, Surcel HM, Dillner J, Faust H. Sustained cross-reactive antibody responses after human papillomavirus vaccinations: up to 12 years follow-up in the Finnish maternity cohort. J Infect Dis. 2021;223:1992\u20132000.","journal-title":"J Infect Dis"},{"key":"4170_CR68","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/j.vaccine.2022.01.041","volume":"40","author":"K Panwar","year":"2022","unstructured":"Panwar K, Godi A, Cocuzza CE, Andrews N, Southern J, Turner P, et al. Binding antibody levels to vaccine (HPV6\/11\/16\/18) and non-vaccine (HPV31\/33\/45\/52\/58) HPV antigens up to 7 years following immunization with either Cervarix\u00ae or Gardasil\u00ae vaccine. Vaccine. 2022;40:1198\u2013202.","journal-title":"Vaccine"},{"issue":"Suppl 7","key":"4170_CR69","doi-asserted-by":"publisher","first-page":"H71","DOI":"10.1016\/j.vaccine.2013.04.086","volume":"31","author":"J Berkhof","year":"2013","unstructured":"Berkhof J, Bogaards JA, Demirel E, Diaz M, Sharma M, Kim JJ. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia. Vaccine. 2013;31(Suppl 7):H71\u20139.","journal-title":"Vaccine"},{"key":"4170_CR70","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5775","volume":"343","author":"M Jit","year":"2011","unstructured":"Jit M, Chapman R, Hughes O, Choi YH. Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. BMJ. 2011;343: d5775.","journal-title":"BMJ"},{"key":"4170_CR71","doi-asserted-by":"publisher","first-page":"4513","DOI":"10.1016\/j.vaccine.2008.06.045","volume":"26","author":"HW Chesson","year":"2008","unstructured":"Chesson HW, Forhan SE, Gottlieb SL, Markowitz LE. The potential health and economic benefits of preventing recurrent respiratory papillomatosis through quadrivalent human papillomavirus vaccination. Vaccine. 2008;26:4513\u20138.","journal-title":"Vaccine"},{"key":"4170_CR72","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1002\/ijc.31265","volume":"142","author":"IMCM De Kok","year":"2018","unstructured":"De Kok IMCM, Korfage IJ, van den Hout WB, Helmerhorst TJM, Habbema JDF, Essink-Bot M, van Ballegooijen M. Quality of life assumptions determine which cervical cancer screening strategies are cost-effective. Int J Cancer. 2018;142:2383\u201393.","journal-title":"Int J Cancer"},{"key":"4170_CR73","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.brachy.2008.05.001","volume":"7","author":"WM Nijdam","year":"2008","unstructured":"Nijdam WM, Levendag PC, Noever I, Schmitz PIM, Uyl-de Groot CA. Longitudinal changes in quality of life and costs in long-term survivors of tumors of the oropharynx treated with brachytherapy or surgery. Brachytherapy. 2008;7:343\u201350.","journal-title":"Brachytherapy"},{"key":"4170_CR74","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/coa.12502","volume":"41","author":"TM Govers","year":"2016","unstructured":"Govers TM, Schreuder WH, Klop WMC, Grutters JPC, Rovers MM, Merkx MAW, Takes RP. Quality of life after different procedures for regional control in oral cancer patients: cross-sectional survey. Clin Otolaryngol. 2016;41:228\u201333.","journal-title":"Clin Otolaryngol"},{"key":"4170_CR75","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s12916-019-1460-0","volume":"17","author":"CA Aitken","year":"2019","unstructured":"Aitken CA, van Agt HME, Siebers AG, van Kemenade FJ, Niesters HGM, Melchers WJG, et al. Introduction of primary screening using high-risk HPV DNA detection in the Dutch cervical cancer screening programme: a population-based cohort study. BMC Med. 2019;17:228.","journal-title":"BMC Med"},{"key":"4170_CR76","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1093\/aje\/kwt077","volume":"178","author":"MA Vink","year":"2013","unstructured":"Vink MA, Bogaards JA, van Kemenade FJ, de Melker HE, Meijer CJ, Berkhof J. Clinical progression of high-grade cervical intraepithelial neoplasia: estimating the time to preclinical cervical cancer from doubly censored national registry data. Am J Epidemiol. 2013;178:1161\u20139.","journal-title":"Am J Epidemiol"},{"key":"4170_CR77","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s10552-017-0870-6","volume":"28","author":"SA McDonald","year":"2017","unstructured":"McDonald SA, Qendri V, Berkhof J, de Melker HE, Bogaards JA. Disease burden of human papillomavirus infection in the Netherlands, 1989\u20132014: the gap between females and males is diminishing. Cancer Causes Control. 2017;28:203\u201314.","journal-title":"Cancer Causes Control"},{"key":"4170_CR78","doi-asserted-by":"crossref","unstructured":"Bogaards JA, Mooij SH, Xiridou M, Schim van der Loeff MF. Potential effectiveness of prophylactic HPV immunization for men who have sex with men in the Netherlands: a multi-model approach. PLoS Med. 2019; 16:e1002756.","DOI":"10.1371\/journal.pmed.1002756"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04170-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-025-04170-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04170-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T19:02:20Z","timestamp":1749409340000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-025-04170-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,9]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4170"],"URL":"https:\/\/doi.org\/10.1186\/s12916-025-04170-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.12.27.23300574","asserted-by":"object"}]},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,9]]},"assertion":[{"value":"2 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval and consent to participate.Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JAB is co-PI on the investigator-initiated research project \u201cHPV4M: Human papillomavirus vaccine effectiveness study among men who have sex with men\u201d, conducted at the Public Health Service of Amsterdam and financed by GlaxoSmithKline, manufacturer of the bivalent HPV vaccine. BS and JB report no financial relationships or conflicts of interest regarding the content herein.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"339"}}